Catalyst Biosciences is harnessing the catalytic power of engineered human proteases to develop next-generation biopharmaceuticals with improved efficacy and safety in the fight against major diseases.

Focused on drug discovery for hemostasis and complement-driven diseases, age-related macular degeneration and inflammation, Catalyst Biosciences engineers human proteases that initiate or regulate protease driven biological cascades and can inactivate hundreds to thousands of disease-causing target molecules.

Catalyst Biosciences is working independently and with leading industry partners to develop both novel and improved best-in-class versions of current protease-based drugs.

To learn more about the Targacept / Catalyst Definitive Merger Agreement Click Here